Erste Asset Management GmbH Invests $6.27 Million in Insulet Corporation $PODD

Erste Asset Management GmbH purchased a new position in shares of Insulet Corporation (NASDAQ:PODD) in the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 21,889 shares of the medical instruments supplier’s stock, valued at approximately $6,268,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of PODD. NewEdge Advisors LLC lifted its stake in shares of Insulet by 44.8% during the 1st quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock worth $54,000 after acquiring an additional 64 shares during the last quarter. Cresset Asset Management LLC lifted its stake in shares of Insulet by 7.3% during the 2nd quarter. Cresset Asset Management LLC now owns 2,587 shares of the medical instruments supplier’s stock worth $813,000 after acquiring an additional 177 shares during the last quarter. Cerity Partners LLC lifted its stake in shares of Insulet by 68.7% during the 2nd quarter. Cerity Partners LLC now owns 17,262 shares of the medical instruments supplier’s stock worth $5,423,000 after acquiring an additional 7,030 shares during the last quarter. Sei Investments Co. lifted its stake in shares of Insulet by 27.4% during the 2nd quarter. Sei Investments Co. now owns 137,643 shares of the medical instruments supplier’s stock worth $43,245,000 after acquiring an additional 29,584 shares during the last quarter. Finally, Treasurer of the State of North Carolina lifted its stake in shares of Insulet by 2.5% during the 2nd quarter. Treasurer of the State of North Carolina now owns 32,752 shares of the medical instruments supplier’s stock worth $10,290,000 after acquiring an additional 791 shares during the last quarter.

Insider Activity at Insulet

In related news, Director Timothy C. Stonesifer purchased 2,790 shares of Insulet stock in a transaction dated Wednesday, June 3rd. The stock was purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the transaction, the director owned 9,041 shares in the company, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.36% of the company’s stock.

Insulet Trading Up 5.3%

Shares of NASDAQ PODD opened at $159.61 on Wednesday. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. The business has a fifty day simple moving average of $173.43 and a two-hundred day simple moving average of $235.68. The firm has a market cap of $11.05 billion, a PE ratio of 37.12, a price-to-earnings-growth ratio of 1.19 and a beta of 1.13. Insulet Corporation has a twelve month low of $140.63 and a twelve month high of $354.88.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The business had revenue of $761.70 million during the quarter, compared to analyst estimates of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.Insulet’s revenue was up 33.9% on a year-over-year basis. During the same period in the previous year, the company posted $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Analysts expect that Insulet Corporation will post 6.46 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

PODD has been the subject of a number of research analyst reports. Bank of America decreased their price target on Insulet from $288.00 to $208.00 and set a “buy” rating for the company in a research note on Monday, May 18th. JPMorgan Chase & Co. decreased their price target on Insulet from $340.00 to $275.00 and set an “overweight” rating for the company in a research note on Thursday, May 7th. Raymond James Financial set a $216.00 price target on Insulet in a research note on Monday. Robert W. Baird decreased their target price on Insulet from $360.00 to $248.00 in a research report on Thursday, May 7th. Finally, Barclays decreased their target price on Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a research report on Thursday, May 7th. Twenty-one equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Insulet has an average rating of “Moderate Buy” and an average price target of $250.00.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.